Statement from Research!America President and CEO Mary Woolley on the House Passage of the 21st Century Cures Act
The House bipartisan passage of the 21st Century Cures Act is a triumph for patients and a true testament to what can be accomplished when patients and other research stakeholders engage with policymakers and commit to finding solutions to our most pressing health threats. We are pleased that the bill includes support for national priorities like the Cancer Moonshot, Precision Medicine and BRAIN Initiatives. Importantly, the bill helps empower the Food and Drug Administration to recruit the best and the brightest scientific minds, paves the way for more patient involvement in the discovery, development and delivery pipeline, and fosters young researchers to help secure our nation’s global scientific leadership. We are grateful that members of Congress from both sides of the aisle persevered until they found a common path to faster medical progress, and that they coupled the 21st Century Cures Act with initiatives to combat the opioid crisis and help patients facing mental illness. We are disappointed that policymakers chose to redirect future increases in the Prevention and Public Health Fund to help offset the cost of this legislation, since that fund is a strategic investment in its own right. Nonetheless, we believe this bill richly deserves the bipartisan support it enjoys, and we urge the Senate to pass and the President to sign it. Finding solutions for deadly and debilitating health threats and combating insidious public health threats should be a dual imperative for our nation, and this legislation could well usher in an era of unprecedented progress on both fronts.